IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baldwin, S. L.
Right arrow Articles by Orme, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baldwin, S. L.
Right arrow Articles by Orme, I. M.

 Previous Article  |  Next Article 

Infect Immun, June 1998, p. 2951-2959, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Evaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis

Susan L. Baldwin,1 Celine D'Souza,1 Alan D. Roberts,1 Brian P. Kelly,1 Anthony A. Frank,2 Margaret A. Lui,3 Jeffrey B. Ulmer,3 Kris Huygen,4 David M. McMurray,5 and Ian M. Orme1,*

Mycobacteria Research Laboratories, Department of Microbiology,1 and Department of Pathology,2 Colorado State University, Fort Collins, Colorado 80523; Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania 194863; Department of Virology, Pasteur Institute, B-1180 Brussels, Belgium4; and Department of Medical Microbiology and Immunology, Texas A&M University, College Station, Texas 778435

Received 20 October 1997/Returned for modification 8 January 1998/Accepted 12 March 1998

The results of this study provide the first evidence that two completely separate vaccine approaches, one based on a subunit vaccine consisting of a mild adjuvant admixed with purified culture filtrate proteins and enhanced by the cytokine interleukin-2 and the second based on immunization with DNA encoding the Ag85A protein secreted by Mycobacterium tuberculosis, could both prevent the onset of caseating disease, which is the hallmark of the guinea pig aerogenic infection model. In both cases, however, the survival of vaccinated guinea pigs was shorter than that conferred by Mycobacterium bovis BCG, with observed mortality of these animals probably due to consolidation of lung tissues by lymphocytic granulomas. An additional characteristic of these approaches was that neither induced skin test reactivity to commercial tuberculin. These data thus provide optimism that development of nonliving vaccines which can generate long-lived immunity approaching that conferred by the BCG vaccine is a feasible goal.

* Corresponding author. Mailing address: Mycobacteria Research Laboratories, Department of Microbiology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-5777. Fax: (970) 491-5125. E-mail: iorme{at}lamar.colostate.edu.

Infect Immun, June 1998, p. 2951-2959, Vol. 66, No. 6
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 1998 by the American Society for Microbiology. All rights reserved.